Skip to main content

Advertisement

SpringerLink
Log in

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study. Peptides were determined based on the presence of peptide-specific cytotoxic T lymphocyte precursors and IgG in each patient. A maximum of four peptides were subcutaneously administered weekly with UFT (300 mg/m2 day−1) and UZEL (75 mg/day) for 4 weeks, followed by 1 week of rest. This therapy was well-tolerated although there was a grade-3 skin reaction at the vaccination site in one patient. An increase in peptide-specific interferon-γ production or peptide-specific IgG after the tenth vaccination was observed in nine of ten or eight of ten patients tested, respectively. IgG responses were well correlated with overall survival (P = 0.0215). The safety and immunological responsiveness of the present therapy suggest that this combination would be of clinical benefit for mCRC patients, and further trials are merited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Antony PA, Piccirillo CA, Akpinarli A et al (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4 + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601

    PubMed  CAS  Google Scholar 

  2. Barve M, Bender J, Senzer N et al (2008) Induction of immune response and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 27:4418–4425

    Article  Google Scholar 

  3. Becker JC, Wobser M, Hofmeister V et al (2008) Safety, immunologenicity and clinical response of a survivin-based peptide vaccine in therapy-resistant advanced cancer: Results from phase I/II trial. Abstract of Annual Meeting of American Society of Clinical Oncology J Clin Oncol 26:3046, 143pp

  4. Bolonaki I, Kotsakis A, Papadimitraki E et al (2007) Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 25:2727–2734

    Article  PubMed  CAS  Google Scholar 

  5. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616

    Article  PubMed  CAS  Google Scholar 

  6. Harashima N, Tanaka K, Sasatomi T et al (2001) Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 31:323–332

    Article  PubMed  CAS  Google Scholar 

  7. Hida N, Maeda Y, Katagiri K et al (2002) A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51:219–228

    Article  PubMed  CAS  Google Scholar 

  8. Ito M, Shichijo S, Miyagi Y et al (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88:633–639

    Article  PubMed  CAS  Google Scholar 

  9. Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693–1702

    Article  PubMed  CAS  Google Scholar 

  10. Kikuchi M, Nakao M, Inoue Y et al (1999) Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81:459–466

    Article  PubMed  CAS  Google Scholar 

  11. Komatsu N, Shichijo S, Nakagawa M et al (2004) New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Inest 64:535–545

    Article  CAS  Google Scholar 

  12. Mine T, Sato Y, Noguchi M et al (2004) Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10:929–937

    Article  PubMed  CAS  Google Scholar 

  13. Miyagi Y, Imai N, Sasatomi T et al (2001) Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptide. Clin Cancer Res 12:3950–3962

    Google Scholar 

  14. Nakao M, Shichijo S, Imaizumi T et al (2000) Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164:2565–2574

    PubMed  CAS  Google Scholar 

  15. Noguchi M, Mine T, Yamada A et al (2007) Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 16:341–349

    PubMed  Google Scholar 

  16. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170

    Article  PubMed  CAS  Google Scholar 

  17. Sasatomi T, Suefuji Y, Matsunaga K et al (2002) Expression of tumor rejection antigens in colorectal carcinomas. Cancer 94:1636–1641

    Article  PubMed  Google Scholar 

  18. Sato Y, Fujiwara T, Mine T et al (2007) Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 7:1113–1119

    Article  Google Scholar 

  19. Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474

    Article  PubMed  CAS  Google Scholar 

  20. Ullenhag GJ, Frödin JE, Jeddi-Tehrani M et al (2004) Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 15:3273–3328

    Article  Google Scholar 

  21. Wood C, Srivastava P, Bukowski R et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145–154

    Article  PubMed  CAS  Google Scholar 

  22. Yajima N, Yamanaka R, Mine T et al (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11:5900–5911

    Article  PubMed  CAS  Google Scholar 

  23. Yanagimoto H, Mine T, Yamamoto K et al (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 12:605–611

    Article  Google Scholar 

  24. Yang D, Nakao M, Shichijo S et al (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59:4056–4063

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan

    Takashi Hattori, Hitoshi Shiozaki & Kiyotaka Okuno

  2. Multidisciplinary Treatment Center, Kurume University School of Medicine, Kurume, Japan

    Takashi Mine

  3. Department of Immunology, Kurume University School of Medicine, Kurume, Japan

    Takashi Mine, Nobukazu Komatsu & Kyogo Itoh

  4. Cancer Vaccine Division of Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan

    Akira Yamada & Kyogo Itoh

Authors
  1. Takashi Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Mine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobukazu Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyogo Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hitoshi Shiozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kiyotaka Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiyotaka Okuno.

Additional information

T. Hattori and T. Mine equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hattori, T., Mine, T., Komatsu, N. et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 58, 1843–1852 (2009). https://doi.org/10.1007/s00262-009-0695-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-009-0695-6

Keywords

Search

Navigation